Another Zolgensma red flag, another delay in data reporting at Novartis' AveXis | Fierce Pharma
AveXis Issues Community Statement on AVXS-101 Clinical Hold - Cure SMA
FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy
AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
AveXIS Announcement – Utah Program for Inherited Neuromuscular Disorders
g925518.jpg
avxs_Current_Folio_10K
AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
g944461.jpg
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
AveXis Gene Therapy Manufacturing Facility, North Carolina, USA
AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center
AveXis Inc.: Buy at the High? | The Motley Fool
AveXis steps up gene therapy pursuit of Biogen's SMA pathfinder | Fierce Biotech
The world's most expensive drug?
A 2nd Patient Death Reported in Novartis' Gene Therapy Trial | BioSpace
Novartis-bound AveXis posts early look at data from pivotal SMA gene therapy trial | Fierce Biotech
Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy
Promising results in phase 1 SMA gene therapy trial - Muscular Dystrophy Association
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
AveXis Knew of 'Manipulated' Data in Zolgensma Application, FDA Says
AveXis chooses BIA Separations to support gene therapy pipeline
Avexis — PBM Capital
